2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P1520
    Prolactin Releasing Peptide (1-31), human 215510-22-8 99.51%
    Prolactin Releasing Peptide (1-31), human is a high affinity GPR10 ligand that cause the release of the prolactin. Prolactin Releasing Peptide (1-31) binds to GPR10 for human and rats with Ki values of 1.03 nM and 0.33 nM, respectively. Prolactin Releasing Peptide (1-31) can be used for the research of the hypothalamo-pituitary axis.
    Prolactin Releasing Peptide (1-31), human
  • HY-P1821
    Myelin Basic Protein 126768-94-3 98.98%
    Myelin Basic Protein (MHP4-14), a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca2+/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts.
    Myelin Basic Protein
  • HY-P1904
    Phe-Met-Arg-Phe Like Peptide, Snail Helix aspersa 98495-35-3 99.70%
    Phe-Met-Arg-Phe Like Peptide, Snail Helix aspersa is a FMRF-like peptide from visceral and somatic muscles of the snail Helix aspersa. FMRF (Phe-Met-Arg-Phe) is a neuropeptide peptide consisting of 4 amino acid residues.
    Phe-Met-Arg-Phe Like Peptide, Snail Helix aspersa
  • HY-P2155
    BigLEN(rat) 369377-66-2 98.98%
    BigLEN(rat) is a potent GPR171 agonist with an EC50 of 1.6 nM.
    BigLEN(rat)
  • HY-P2277
    PEN (rat) 569364-13-2 99.24%
    PEN (rat), one of the most abundant hypothalamic neuropeptide and derived from the proprotein ProSAAS, is an endogenous ligand of GPR83.
    PEN (rat)
  • HY-P2307
    Tat-NR2Baa 847829-41-8
    Tat-NR2BAA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95.
    Tat-NR2Baa
  • HY-P2602
    α-Casozepine 117592-45-7 99.36%
    α-Casozepine is a bioactive peptide derived from the α protein S1 casein in milk and has an affinity for γ-aminobutyric acid (GABA) receptors in the brain. α-Casozepine has anti-anxiety effects.
    α-Casozepine
  • HY-P3117
    PACAP (6-27) (human, ovine, rat) 136134-68-4 98.89%
    PACAP (6-27) (human, ovine, rat) is a PACAP receptor antagonist that blocks the canine adrenal catecholamine response to exogenous vasoactive intestinal peptide (VIP). PACAP (6-27) (human, ovine, rat) has the potential to study cardiovascular and neurological diseases.
    PACAP (6-27) (human, ovine, rat)
  • HY-P3801
    [Glp5,(Me)Phe8,Sar9] Substance P (5-11) 77128-69-9 99.61%
    [Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats.
    [Glp5,(Me)Phe8,Sar9] Substance P (5-11)
  • HY-P3840
    Head activator neuropeptide 79943-68-3 99.50%
    Head activator neuropeptide is a mitogen for mammalian cell lines of neuronal or neuroendocrine origin. Head activator neuropeptide signals by binding GPR37 and stimulates cells to enter mitosis.
    Head activator neuropeptide
  • HY-P4678
    (Phe2,Orn8)-Oxytocin 2480-41-3 98.22%
    (Phe2,Orn8)-Oxytocin is a selective V1 vasopressin agonist. (Phe2,Orn8)-Oxytocin induces a sustained contractility of rabbit epididymis with EC50 value of 280 nM.
    (Phe2,Orn8)-Oxytocin
  • HY-100130
    N-[(4-Aminophenyl)methyl]adenosine 95523-13-0 ≥98.0%
    N-[(4-Aminophenyl)methyl]adenosine is a adenosine receptor inhibitor, with Ki of 29 nM for Rat ecto-5′-Nucleotidase.
    N-[(4-Aminophenyl)methyl]adenosine
  • HY-100170
    5-HT4 antagonist 1 261766-73-8 98.95%
    5-HT4 antagonist 1 is a 5-HT4 receptor antagonist with a pKi of 9.6.
    5-HT4 antagonist 1
  • HY-100238
    Antihistamine-1 1186430-60-3 99.45%
    Antihistamine-1 is a H1-antihistamine (Ki=6.9 nM) with acceptable blood-brain barrier penetration and also an inhibitor of CYP2D6 and hERG channel with IC50s of 5.4 and 0.8 μM, respectively.
    Antihistamine-1
  • HY-100336
    AC260584 560083-42-3 99.60%
    AC260584 is an M1 muscarinic receptor allosteric agonist with a pEC50 of 7.6.
    AC260584
  • HY-100405
    FTIDC 873551-53-2
    FTIDC is an orally active, noncompetitive, selective allosteric metabotropic glutamate receptor (mGluR) 1 antagonist with an IC50 of 5.8 nM for human mGluR1a. FTIDC has no species differences in its antagonistic activity on recombinant human, mouse, and rat mGluR1.
    FTIDC
  • HY-100547
    IEM-1754 162831-31-4 98.03%
    IEM-1754, a dicationic adamantane derivative, is a potent blocker of open channels of native ionotropic glutamate receptors including quisqualate-sensitive receptors in insect muscles, NMDAR in cultured rat cortical neurons, and AMPAR in freshly isolated hippocampal cells. IEM-1754 shows anticonvulsant potency in vivo.
    IEM-1754
  • HY-100658
    Didesmethyl cariprazine 839712-25-3 99.79%
    Didesmethyl cariprazine is a metabolite of Cariprazine and acts as the predominant circulating active moiety. Didesmethyl cariprazine has a long half-life of 1-3 weeks. Cariprazine is a antipsychotic agent candidate that exhibits high affinity for the D3 and D2 receptors, and moderate affinity for the 5-HT1A receptor.
    Didesmethyl cariprazine
  • HY-100705
    DMNB 20357-25-9 98.76%
    DMNB (6-Nitroveratraldehyde), a precursor, can be used for the synthesis no-carrier-added 6-[18F]fluoro-L-DOPA (6-FDOPA). No-Carrier-Added (NCA) 6-[18F]fluoro-L-dopa (6-FDOPA) is being produced routinely for PET investigations of dopaminergic systems.
    DMNB
  • HY-100727
    AM-2099 1443373-17-8 98.06%
    AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel Nav1.7 with an IC50 of 0.16 μM for human Nav1.7.
    AM-2099
Cat. No. Product Name / Synonyms Application Reactivity